Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B
/PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced positive long-term results from the Phase 3 HOPE-B clinical trial evaluating...
Vita Cslbehring Wolfgang Miesbach Etranacogene Dezaparvovec European Association Of Haemophilia University Hospital Of Frankfurt Head Of The Department Coagulation Disorders
Source: prnewswire.com